AI-Driven Discovery
of Genetic Medicines

Brian O'Callaghan is the Chief Executive Officer and board member of Deep Genomics. With over 30 years experience as a senior life science executive, Brian brings extensive knowledge within the biotech, big pharma and clinical research organization (CRO) sectors. Previously, he held CEO positions at ObsEva SA, Petra Pharma, Acucela, Sangart and BioPartners. Earlier in his career, Brian held multiple senior management positions at Pfizer, Merck Serono, Novartis, Covance and NPS Pharmaceuticals. Brian received a Marketing Diploma from the Marketing Institute of Ireland and a Master of Business Administration (MBA) from the Henley Business School at the University of Reading.

Brendan Frey is an internationally acclaimed entrepreneur, engineer and scientist. He is Chief Innovation Officer, Founder and board member of Deep Genomics and co-founder of the Vector Institute for Artificial Intelligence. Brendan made fundamental contributions in the fields of deep learning, genomic medicine, and information technology. He co-authored over 200 papers in these areas, including over a dozen that appeared in Nature, Science and Cell. His work with Geoffrey Hinton on the 'wake-sleep algorithm' helped to launch the field of deep learning (Science 1995). This work led to the founding of Deep Genomics in 2015, the first AI system for predicting pathogenic mutations and identifying therapeutic targets. Brendan is Professor of Engineering and Medicine at the University of Toronto and a Fellow of the Royal Society of Canada. Brendan received his Ph.D. from the University of Toronto in 1997.

David B. Johnston, Chief Financial Officer, brings over thirty years of senior financial leadership experience. Currently he is principal of dbjconsulting llc, providing financial and strategic advice to emerging life science companies. Most recently he was Chief Financial Officer for ImmunoGen, Inc., an oncology-focused biotech based in Waltham, MA, where he led several public offerings as well as a creative, non-dilutive royalty financing. Prior to ImmunoGen, Dave served as CFO for Aveo Oncology and Genzyme Biosurgery, where he led both of their initial public offerings. Mr. Johnston earned a B.S. at Washington and Lee University and an MBA at the University of Michigan.

Clive Bertram is the Chief Business Officer at Deep Genomics. He comes with over 30 years of experience in commercialization, strategic, corporate and business development in the pharmaceutical industry. Most recently, he served as CCO at ObsEva, Petra Pharma and Sangart. Prior to his CCO roles, Clive held multiple senior management positions at Pharmion Limited, Chiron Biopharmaceuticals, Celltech and Eli Lilly. He holds a BSc (Hons.) in Pharmacology and Chemistry from the University of Sheffield.

Tom Masterson is the Chief Operating Officer at Deep Genomics. Holding responsibility for the Project Management Office and executive function, Tom brings structure and continuity to the company, ensuring that corporate goals are supported by the work of our employees. Prior to Deep Genomics, Tom spent time in medical devices, contract research, and healthcare design strategy, before launching his own startup, Caregiver Support Technologies. Tom received his B.Sc. from the University of British Columbia, where he focused on Cell Biology and Genetics. He later received his M.B.A. at Harvard Business School.

Greg Hoffman is the Chief Scientific Officer at Deep Genomics, leading the team responsible for generating rich data sets to train and validate our AI platform by applying state of the art capabilities in cell biology, molecular biology, robotics, screening, and animal models. Greg brings over 20 years of experience in the biotechnology and pharmaceutical sector, including leadership roles at Arbor Biotechnology, Obsidian Therapeutics, Sana Biotechnology, and Novartis. Greg earned his BA in Biochemistry and PhD in Biophysics at Cornell and completed his postdoctoral studies at Harvard Medical School.